Saltar al contenido
Merck

Mistimed origin licensing and activation stabilize common fragile sites under tight DNA-replication checkpoint activation.

Nature structural & molecular biology (2023-04-07)
Olivier Brison, Stefano Gnan, Dana Azar, Stéphane Koundrioukoff, Rodrigo Melendez-Garcia, Su-Jung Kim, Mélanie Schmidt, Sami El-Hilali, Yan Jaszczyszyn, Anne-Marie Lachages, Claude Thermes, Chun-Long Chen, Michelle Debatisse
RESUMEN

Genome integrity requires replication to be completed before chromosome segregation. The DNA-replication checkpoint (DRC) contributes to this coordination by inhibiting CDK1, which delays mitotic onset. Under-replication of common fragile sites (CFSs), however, escapes surveillance, resulting in mitotic chromosome breaks. Here we asked whether loose DRC activation induced by modest stresses commonly used to destabilize CFSs could explain this leakage. We found that tightening DRC activation or CDK1 inhibition stabilizes CFSs in human cells. Repli-Seq and molecular combing analyses showed a burst of replication initiations implemented in mid S-phase across a subset of late-replicating sequences, including CFSs, while the bulk genome was unaffected. CFS rescue and extra-initiations required CDC6 and CDT1 availability in S-phase, implying that CDK1 inhibition permits mistimed origin licensing and firing. In addition to delaying mitotic onset, tight DRC activation therefore supports replication completion of late origin-poor domains at risk of under-replication, two complementary roles preserving genome stability.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Hydroxyurea, 98%, powder
Sigma-Aldrich
Cdk1 Inhibitor IV, RO-3306, RO-3306 is a cell-permeable, potent and ATP-competitive inhibitor of Cdk1 (Ki = 35 nM and 110 nM for Cdk1/B1 and Cdk1/A, respectively).